MedPath

Study the effectiveness of outpateint treatment of cystic fibrosis exacerbatio

Phase 2
Conditions
Cystic Fibrosis.
Cystic fibrosis
Registration Number
IRCT20191112045413N2
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
29
Inclusion Criteria

Documented diagnosis of CF
Exacerbation phase
Older than 6 years

Exclusion Criteria

Patients unable to perform pulmonary tests because of physical or mental limitations

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percent of patients with increased FEV1 values. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: Spirometry machine.;Percent of patients with decreased residual volumes of lungs. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: body box (plethysmograph) machines.;Percent of patients with increased total lung capacities of lungs. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: body box (plethysmograph) machines.;Percent of patients with decreased airway resistance. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: Impulse oscillometry machine.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath